Table 2.
Summary of meta-analysis results: categorical and continuous outcomes
| Outcome | Included studies, n | Intervention | Control | Risk ratio M-H, random (95% CI) | Heterogeneity, I2 | |||
|
|
|
|||||||
| Events | Total | Events | Total | |||||
| At 4.7–6 years: categorical outcomes | ||||||||
| Mortality | Mortality (all-cause) | 4 | 199 | 1402 | 253 | 1401 | 0.79 (0.66 to 0.93) | 0% |
|
| ||||||||
| Cardiac cause of death | 4 | 128 | 1384 | 174 | 1385 | 0.74 (0.58 to 0.94) | 12% | |
|
| ||||||||
| Risk factor management | BP within guidelines | 3 | 624 | 1016 | 623 | 1005 | 0.95 (0.83 to 1.09) | 61% |
|
| ||||||||
| Total cholesterol within guidelines | 3 | 417 | 950 | 397 | 879 | 0.98 (0.89 to 1.07) | 0% | |
|
| ||||||||
| Secondary prevention prescribing | Aspirin prescribed | 3 | 687 | 958 | 631 | 939 | 1.06 (1.00 to 1.12) | 39% |
|
| ||||||||
| Statins prescribed | 2 | 212 | 472 | 213 | 493 | 1.09 (0.77 to 1.53) | 75% | |
|
| ||||||||
| At 10 years: categorical outcomes | ||||||||
| Mortality | Mortality (all-cause) | 2 | 257 | 672 | 283 | 674 | 0.91 (0.75 to 1.09) | 3% |
|
| ||||||||
| Cardiac cause of death | 2 | 152 | 672 | 160 | 674 | 0.95 (0.79 to 1.16) | 0% | |
|
| ||||||||
| At 4.7–6 years: continuous outcomes | ||||||||
| Outcome | Included studies, n | Intervention, n | Control, n | Mean differenceb (95% CI) | Heterogeneity, I2 | |||
|
| ||||||||
| Risk factor management | Mean difference systolic BP (mmHg) | 2 | 469 | 466 | 1.94 (−3.02 to 6.91) | 70% | ||
|
| ||||||||
| Mean difference total cholesterol (mmol/l) | 2 | 362 | 358 | 0.03 (−0.12 to 0.18) | 0% | |||
BP = blood pressure.
Mantel-Haenszel, random effects.
Inverse variance, random effects.